DNAJB4与非小细胞肺癌免疫细胞浸润和患者预后的相关性分析

doi:10.3969/j.issn.1004-616x.2023.06.011

癌变·畸变·突变 ›› 2023, Vol. 35 ›› Issue (6): 467-472.doi: 10.3969/j.issn.1004-616x.2023.06.011

DNAJB4与非小细胞肺癌免疫细胞浸润和患者预后的相关性分析

杨上英^1,4, 黄明翔^1,4, 许德新^2,4, 刘加夫^3,4, 陈新富^2,4

1. 福建省福州肺科医院检验科, 福建福州 350008;
2. 福建省福州肺科医院胸外科, 福建福州 350008;
3. 福建省福州肺科医院病理科, 福建福州 350008;
4. 福建医科大学临床教学医院检验科, 福建福州 350008

收稿日期:2023-06-21 修回日期:2023-09-25 出版日期:2023-11-30 发布日期:2023-12-09
作者简介:杨上英，E-mail：ysy8009@163.com
基金资助:
福建省福州市科技计划项目(2016-S-129)

Expression of DNAJB4 and association with immune infiltration and prognosis in non-small cell lung cancer

YANG Shangying^1,4, HUANG Mingxiang^1,4, XU Dexin^2,4, LIU Jiafu^3,4, CHEN Xinfu^2,4

1. Department of Clinical Laboratory, Fujian Pulmonary Hospital, Fuzhou 350008;
2. Department of Chest Surgery, Fujian Pulmonary Hospital, Fuzhou 350008;
3. Department of Pathology, Fujian Pulmonary Hospital, Fuzhou 350008;
4. Department of Clinical Laboratory, Clinical Teaching Hospital of Fujian Medical University, Fuzhou 350008, Fujian, China

Received:2023-06-21 Revised:2023-09-25 Online:2023-11-30 Published:2023-12-09

摘要/Abstract

摘要： 目的：探讨DNAJB4在非小细胞肺癌(NSCLC)中的表达，分析其与癌组织中免疫细胞浸润水平和NSCLC患者预后的相关性。方法：采用GEPIA数据库分析NSCLC患者癌组织和癌旁正常组织中DNAJB4 mRNA的表达差异。采用荧光定量PCR和免疫组织化学方法检测组织中DNAJB4 mRNA和蛋白的表达。应用TIMER数据库分析DNAJB4表达与NSCLC中免疫细胞(B细胞、CD4⁺ T细胞、CD8⁺ T细胞、中性粒细胞、巨噬细胞、树突状细胞)浸润水平的相关性，并探讨免疫细胞浸润对NSCLC患者预后的影响。通过Kaplan-Meier plotter数据库分析DNAJB4表达水平与NSCLC预后的关系。结果：与癌旁正常组织比较，DNAJB4在NSCLC组织中低表达(P<0.05)。DNAJB4表达水平与癌组织免疫细胞的浸润程度相关。肺腺癌中，DNAJB4的拷贝数变异对免疫细胞的浸润水平有明显影响(P<0.05)。B细胞可作为肺腺癌预后的独立危险因素。肺鳞癌中，DNAJB4拷贝数变异对除CD8⁺ T细胞外的免疫细胞浸润水平有显著影响(P<0.05)。生存分析显示低表达的DNAJB4与NSCLC患者的不良预后显著相关(P<0.05)。结论：DNAJB4在NSCLC组织中表达下调，参与NSCLC免疫细胞浸润，影响免疫微环境的平衡，进而造成NSCLC患者的不良预后。DNAJB4可能是NSCLC免疫细胞浸润及预后的生物学标志物。

关键词: DnaJ热休克蛋白家族成员B4, 非小细胞肺癌, 免疫浸润, 预后

Abstract: OBJECTIVE：To investigate expression of DNAJB4 in non-small cell lung cancer (NSCLC) and its association with immune cell infiltration levels and prognosis. METHODS：Differences in expression of DNAJB4 mRNA in cancer tissues of NSCLC patients and normal tissues adjacent to the cancers were evaluated based on GEPIA database analysis. Real-time quantitative PCR and immunohistochemical methods were used to detect expressions of DNAJB4 mRNA and protein in NSCLC tissues. The TIMER database was used to analyze correlations between the expression of DNAJB4 and the level of immune cells (B cells，CD4⁺T cells，CD8⁺T cells，neutrophils，macrophages，dendritic cells) infiltration in NSCLC，and to explore the prognosis of NSCLC patients with immune cell infiltration. Relationships between expression levels of DNAJB4 and prognosis of NSCLC were evaluated using the Kaplan Meier plot database. RESULTS：Expression of DNAJB4 in NSCLC tissues was lower than that of normal tissues. The low expression was associated with the infiltration levels of immune cells. In lung adenocarcinoma，copy number variations of DNAJB4 had a significant impact on the infiltration levels of immune cells (P<0.05). In addition，B cells served as independent prognostic factors for LUAD. In lung squamous cell carcinoma (LUSC)，DNAJB4 copy number variations had a significant impact on immune cell infiltration levels except for CD8⁺ T cells (P<0.05). Survival analysis showed a significant correlation between low expression of DNAJB4 and poor prognosis in NSCLC patients (P<0.05). CONCLUSION：DNAJB4 expression in NSCLC tissues was downregulated，involved in immune cell infiltration into cancer tissues，impacted on the balance of immune microenvironment，and adversely affected prognosis of the patients. DNAJB4 may be useful as a biological marker for immune cell infiltration and prognosis in NSCLC.

Key words: DNAJB4, non-small cell lung cancer, immune infiltration, prognosis

中图分类号:

R730.2

杨上英, 黄明翔, 许德新, 刘加夫, 陈新富. DNAJB4与非小细胞肺癌免疫细胞浸润和患者预后的相关性分析[J]. 癌变·畸变·突变, 2023, 35(6): 467-472.

YANG Shangying, HUANG Mingxiang, XU Dexin, LIU Jiafu, CHEN Xinfu. Expression of DNAJB4 and association with immune infiltration and prognosis in non-small cell lung cancer[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(6): 467-472.

参考文献

[1] KO E C,RABEN D,FORMENTI S C. The integration of radiotherapy with immunotherapy for the treatment of non-small cell lung cancer[J]. Clin Cancer Res,2018,24(23):5792-5806.
[2] BABA Y,NOMOTO D,OKADOME K,et al. Tumor immune microenvironment and immune checkpoint inhibitors in esophageal squamous cell carcinoma[J]. Cancer Sci,2020,111(9):3132-3141.
[3] 崔艺蒙,邢影,蔡莉. 肿瘤浸润性免疫细胞在肺癌微环境中的作用[J]. 肿瘤学杂志,2019,25(11):941-946.
[4] TAN X X,ZHANG X H,CHEN K,et al. The biologic properties of HLJ1 in hepatocellular carcinoma cells[J]. Int J Clin Exp Pathol,2017,10(3):2879-2886.
[5] LIU Y,ZHOU J,ZHANG C W,et al. HLJ1 is a novel biomarker for colorectal carcinoma progression and overall patient survival[J]. Int J Clin Exp Pathol,2014,7(3):969-977.
[6] ACUN T,DOBERSTEIN N,HABERMANN J K,et al. HLJ1(DNAJB4) gene is a novel biomarker candidate in breast cancer[J]. OMICS,2017,21(5):257-265.
[7] TANG Z F,LI C W,KANG B X,et al. GEPIA:a web server for cancer and normal gene expression profiling and interactive analyses[J]. Nucleic Acids Res,2017,45(W1):W98-W102.
[8] LI T W,FU J X,ZENG Z X,et al. TIMER2.0 for analysis of tumor-infiltrating immune cells[J]. Nucleic Acids Res,2020,48(W1):W509-W514.
[9] CHEN H W,LEE J Y,HUANG J Y,et al. Curcumin inhibits lung cancer cell invasion and metastasis through the tumor suppressor HLJ1[J]. Cancer Res,2008,68(18):7428-7438.
[10] SIM-ES-CORREIA J,SILVA D I,MELO S,et al. DNAJB4 molecular chaperone distinguishes WT from mutant E-cadherin,determining their fate in vitro and in vivo[J]. Hum Mol Genet,2014,23(8):2094-2105.
[11] MIAO W L,LI L,WANG Y S. A targeted proteomic approach for heat shock proteins reveals DNAJB4 as a suppressor for melanoma metastasis[J]. Anal Chem,2018,90(11):6835-6842.
[12] SHE K L,YU S Q,HE S S,et al. CircRNA 0009043 suppresses non-small-cell lung cancer development via targeting the miR-148a-3p/DNAJB4 axis[J]. Biomark Res,2022,10(1):61.
[13] FANG F,MO L L,PAN X F,et al. DNAJB4 promotes triple-negative breast cancer cell apoptosis via activation of the Hippo signaling pathway[J]. Discov Oncol,2023,14(1):40.
[14] MIAO W L,LI L,WANG Y S. A targeted proteomic approach for heat shock proteins reveals DNAJB4 as a suppressor for melanoma metastasis[J]. Anal Chem,2018,90(11):6835-6842.
[15] WAN H H,LIU Z H,TAN X X,et al. Application of immune cell infiltration in the diagnosis and prognosis of non-small cell lung cancer[J]. Chin J Biotechnol,2020,36(4):740-749.
[16] LARGEOT A,PAGANO G,GONDER S,et al. The B-side of cancer immunity:the underrated tune[J]. Cells,2019,8(5):449.
[17] NELSON B H. CD20+ B cells:the other tumor-infiltrating lymphocytes[J]. J Immunol,2010,185(9):4977-4982.

DNAJB4与非小细胞肺癌免疫细胞浸润和患者预后的相关性分析

Expression of DNAJB4 and association with immune infiltration and prognosis in non-small cell lung cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	朱文标, 丘波, 谢寿城, 肖焕钦, 刘高敏. 跨膜蛋白79在肝细胞癌中的表达及临床意义[J]. 癌变·畸变·突变, 2023, 35(6): 426-430.
[2]	许金花, 李静静, 吴国峰, 任亚俊, 王雪, 张骞云. 非小细胞肺癌患者血清miR-146a与TNF-α、Treg的相关性及其对预后判断的价值[J]. 癌变·畸变·突变, 2023, 35(6): 462-466.
[3]	高榴, 禹莉. 线粒体转录因子A在肿瘤发生发展中作用的研究进展[J]. 癌变·畸变·突变, 2023, 35(6): 485-488.
[4]	呙文静, 邓慧, 宋萍, 张孟贤. 转化生长因子β诱导蛋白在胶质瘤中的表达及生物学功能[J]. 癌变·畸变·突变, 2023, 35(5): 341-348.
[5]	韦来凤, 洪超群, 陈柳伊, 许镒洧, 伍方财. 实验室炎症相关指标的列线图对预测舌鳞状细胞癌患者手术预后的价值[J]. 癌变·畸变·突变, 2023, 35(5): 366-373.
[6]	杨程晴, 崔永辉, 郑紫恒. 结肠癌患者血清中miR-653-5p的表达及其临床意义[J]. 癌变·畸变·突变, 2023, 35(4): 261-265.
[7]	刘瑞雪, 张力为. 腺苷酸活化蛋白激酶在哈萨克族食管鳞癌组织中的表达及意义[J]. 癌变·畸变·突变, 2023, 35(4): 285-291.
[8]	刘颖, 王蕊, 郭晓, 董律吏, 张艳, 赵银环, 杜芸. 肺腺癌胸腔积液DNA倍体异常与EGFR突变的关系及其对患者预后的影响[J]. 癌变·畸变·突变, 2023, 35(3): 178-182,186.
[9]	王平, 王华勇, 王浩, 雷大军. 骨肉瘤患者血清外泌体中miR-193a和miR-21-5p表达水平及其临床意义[J]. 癌变·畸变·突变, 2023, 35(3): 197-201.
[10]	黄利丹, 吴月明, 王亚帝, 谭琦. EGFR突变型肺腺癌组织中VEGF-A蛋白的表达及其临床意义[J]. 癌变·畸变·突变, 2023, 35(2): 116-120.
[11]	谭健华, 赖姚圳, 唐丽华, 周莉. 2种不同疗法对晚期上皮性卵巢癌的疗效及患者预后影响因素分析[J]. 癌变·畸变·突变, 2023, 35(2): 131-138.
[12]	胡学义, 沈丰, 武伦, 苏才武, 魏涧. SPON2在甲状腺乳头状癌中的表达及其临床意义[J]. 癌变·畸变·突变, 2023, 35(1): 9-14.
[13]	许浩, 胡碧川, 邹伟, 段雅斌. 行根治术的Ⅲ期胃癌患者预后影响因素分析[J]. 癌变·畸变·突变, 2023, 35(1): 30-36.
[14]	路大鹏, 赵卫林, 王玉强, 路洪超, 魏双平. 食管癌生存随访调查及列线图预后预测模型的建立[J]. 癌变·畸变·突变, 2023, 35(1): 37-42.
[15]	靳爽, 李坤, 陈泓润, 张中冕. PIV和AAPR对非小细胞肺癌伴脑转移患者的预后评估价值[J]. 癌变·畸变·突变, 2023, 35(1): 43-48.